Lactobacillus reuteri RC-14

Lactobacillus reuteri RC-14 is a probiotic strain that colonizes the vaginal epithelium and produces hydrogen peroxide, lactic acid, and biosurfactants to competitively exclude pathogenic bacteria. Its primary mechanism involves restoring a Lactobacillus-dominant vaginal microbiome by lowering vaginal pH and inhibiting biofilm formation by Gardnerella vaginalis and other anaerobes.

Origin & History

Lactobacillus reuteri RC-14 is a lactic acid bacterium originally isolated from the human vaginal microbiota and selected for its ability to colonize and maintain vaginal health. This gram-positive, facultative anaerobic bacterium is typically produced as freeze-dried powder in capsule form, standardized by viable cell count (colony-forming units, or CFU). RC-14 is commonly combined with Lactobacillus rhamnosus GR-1 in clinical formulations.

Historical & Cultural Context

The research dossier provides no information regarding historical or traditional use of Lactobacillus reuteri RC-14. This strain is a modern clinical isolate selected through scientific research for specific probiotic properties rather than a traditional fermented food ingredient with documented historical use.

Health Benefits

• Treats and prevents bacterial vaginosis with 88% cure rate when combined with antibiotics vs 40% with antibiotics alone (strong evidence from RCT, PMID: 16697231)
• Achieves 90% bacterial vaginosis cure rate at day 30 when used alone vs 55% with metronidazole gel (moderate evidence from clinical study, PMID: 17045832)
• Promotes 92% complete lactobacilli recolonization in women with vaginosis following antibiotic therapy (moderate evidence from RCT, PMID: 18854803)
• Reduces vaginal yeast and coliform bacteria in healthy women (moderate evidence from RCT, PMID: 12628548)
• May prevent bacterial vaginosis recurrence in HIV-positive women (preliminary evidence from clinical study, PMID: 20801446)

How It Works

Lactobacillus reuteri RC-14 adheres to vaginal epithelial cells via specific surface proteins, displacing pathogenic organisms like Gardnerella vaginalis and Candida species through competitive exclusion. The strain produces hydrogen peroxide, D-lactic acid, and biosurfactants that lower vaginal pH below 4.5, creating an antimicrobial environment that disrupts anaerobic biofilms. It also modulates local innate immunity by downregulating pro-inflammatory cytokines such as IL-8 and TNF-alpha, reducing inflammation associated with dysbiosis.

Scientific Research

Multiple randomized controlled trials have evaluated RC-14, including a double-blind placebo-controlled study of 125 African women with bacterial vaginosis (PMID: 16697231) and a trial comparing probiotic treatment to metronidazole gel in 40 women (PMID: 17045832). Additional RCTs examined vaginal colonization in pregnancy (PMIDs: 32325794, 31362572) and effects in healthy women (PMID: 12628548), with clinical evidence strongest for bacterial vaginosis treatment and prevention.

Clinical Summary

A landmark randomized controlled trial (PMID: 16697231) demonstrated that oral supplementation with Lactobacillus reuteri RC-14 combined with L. rhamnosus GR-1 alongside antibiotics achieved an 88% bacterial vaginosis cure rate versus 40% with antibiotics alone in 64 women. A separate clinical study found an approximately 90% cure rate at day 30 when the probiotic was used as monotherapy compared to 55% with metronidazole gel, suggesting standalone efficacy. Evidence is strongest for bacterial vaginosis prevention and treatment, with moderate-to-strong support from multiple RCTs, though larger trials with longer follow-up periods are still needed. Recurrence rates for bacterial vaginosis appear meaningfully reduced with ongoing probiotic use, though precise recurrence figures vary across study populations.

Nutritional Profile

Lactobacillus reuteri RC-14 is a probiotic microorganism, not a conventional food ingredient, so macronutrient and micronutrient content is not applicable in the traditional dietary sense. As a lyophilized (freeze-dried) probiotic strain, the primary active component is viable bacterial cells, typically delivered at concentrations of 1×10^8 to 1×10^9 CFU (colony-forming units) per dose in commercial formulations. Bioactive compounds produced by or associated with this strain include: (1) Lactic acid and acetic acid — metabolic end-products that contribute to vaginal pH reduction (target pH ≤4.5), supporting a protective acidic microenvironment; (2) Hydrogen peroxide (H2O2) — produced at low micromolar concentrations, contributing to antimicrobial activity against anaerobic pathogens including Gardnerella vaginalis and Prevotella species; (3) Bacteriocin-like inhibitory substances (BLIS) — strain-specific antimicrobial peptides that inhibit competing pathogenic bacteria, exact concentrations vary by production batch; (4) Biosurfactants/co-aggregation factors — surface-layer proteins facilitating adhesion to vaginal epithelial cells and competitive exclusion of pathogens; (5) Short-chain fatty acids (SCFAs) — produced in trace amounts during fermentation. Protein content reflects bacterial cell wall and cytoplasmic proteins (~50–60% of dry cell mass typical of Lactobacillus spp.), with no dietary significance at probiotic doses. Carbohydrate content is negligible at standard dosing. Bioavailability note: Efficacy depends on viable cell survival through delivery vehicle (typically gelatin capsule or vaginal suppository); freeze-drying matrices often include excipients such as maltodextrin or skimmed milk powder that provide minimal caloric contribution (<5 kcal per dose). No clinically relevant vitamin or mineral content is contributed at standard probiotic doses.

Preparation & Dosage

Clinically studied dosages include: 1 × 10⁹ CFU twice daily for 30 days following antibiotic therapy for bacterial vaginosis; two capsules (5 × 10⁹ CFU total) daily for 12 weeks during pregnancy; two capsules nightly for 5 days as standalone BV treatment. Standard formulations contain 1-5 × 10⁹ CFU per dose. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lactobacillus rhamnosus GR-1, vitamin D3, cranberry extract, D-mannose, prebiotics (FOS/GOS)

Safety & Interactions

Lactobacillus reuteri RC-14 is generally recognized as safe (GRAS status) and well-tolerated, with clinical trials reporting no serious adverse events attributable to the strain. Mild gastrointestinal symptoms such as transient bloating or loose stools have been reported infrequently. No clinically significant drug interactions have been documented, though individuals taking immunosuppressant medications should consult a physician before use due to the theoretical risk of bacteremia in severely immunocompromised patients. Data on use during pregnancy are limited but no safety signals have emerged in trials that included pregnant participants; consultation with a healthcare provider is recommended.